This is a randomized, double-blind, placebo-controlled, 8-week intervention clinical study assessing the safety and efficacy of a new low-dose liquid iron supplement in restoring iron levels to normal ranges without promoting constipating side-effects among healthy premenopausal women with non-anemic iron deficiency. The primary outcomes will be an Iron Panel of Serum Iron, Ferritin, Total iron-binding capacity, Transferrin saturation, Complete Blood Count, and high sensitivity - C-Reactive Protein. Secondary outcomes will be surveys on gastrointestinal distress/discomfort and well-being. Adverse events will also be reported.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Serum Iron
Timeframe: Week 0 and Week 8
Serum Ferritin
Timeframe: Week 0 and Week 8
Total Iron-Binding Capacity (TIBC)
Timeframe: Week 0 and Week 8
Transferrin Saturation (tSAT)
Timeframe: Week 0 and Week 8
Complete Blood Count (CBC)
Timeframe: Week 0 and Week 8
High Sensitivity C-Reactive Protein (hs-CRP)
Timeframe: Week 0 and Week 8